Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism

Pharmacological Research

Volumn 118, Issue , 2017, Pages 33-42

  Bertoletti, Laurent ^a,b   Ollier, Edouard ^a,b   Duvillard, Cécile ^a   Delavenne, Xavier ^a,b   Beyens, Marie Noëlle ^a,b   De Magalhaes, Elodie ^a,b   Bellet, Florelle ^a   Basset, Thierry ^a,b   Mismetti, Patrick ^a,b   Laporte, Silvy ^a,b  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b INSERM   (France)

Author keywords

Apixaban; Dabigatran; Direct oral anticoagulant; Edoxaban; Randomized clinical trials; Rivaroxaban

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; ATORVASTATIN; CARBAMAZEPINE; CLARITHROMYCIN; DABIGATRAN ETEXILATE; DIGOXIN; DILTIAZEM; DRONEDARONE; EDOXABAN; ERYTHROMYCIN; FLUCONAZOLE; IDARUCIZUMAB; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; MIDAZOLAM; NAPROXEN; PHENOBARBITAL; PHENYTOIN; PLACEBO; PROTON PUMP INHIBITOR; QUINIDINE; RIFAMPICIN; RITONAVIR; RIVAROXABAN; UNINDEXED DRUG; VERAPAMIL;

ALLERGY; ANTICOAGULANT THERAPY; AREA UNDER THE CURVE; ATRIAL FIBRILLATION; BLEEDING; BREAST FEEDING; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; COMORBIDITY; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GENITAL BLEEDING; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LUNG EMBOLISM; MALIGNANT NEOPLASM; MILD RENAL IMPAIRMENT; NONHUMAN; REVIEW; SEVERE RENAL IMPAIRMENT; TUMOR THROMBUS; URINARY EXCRETION; VENOUS THROMBOEMBOLISM; ACUTE DISEASE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE DISEASE; ADMINISTRATION, ORAL; ANTICOAGULANTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOUS THROMBOEMBOLISM;

EID: 84996629767     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.06.023     Document Type: Review

References (105)

1. [1] Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J., Roth, W., The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab. Dispos. 36 (2008), 386–399.
2. [2] Vakkalagadda, B., Frost, C., Byon, W., Boyd, R.A., Wang, J., Zhang, D., et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. Am. J. Cardiovasc. Drugs, 2016.
3. [3] Matsushima, N., Lee, F., Sato, T., Weiss, D., Mendell, J., Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects. Clin. Pharmacol Drug Dev. 2 (2013), 358–366.
4. [4] Stampfuss, J., Kubitza, D., Becka, M., Mueck, W., The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int. J. Clin. Pharmacol. Ther. 51 (2013), 549–561.
5. [5] Bathala, M.S., Masumoto, H., Oguma, T., He, L., Lowrie, C., Mendell, J., Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab. Dispos. 40 (2012), 2250–2255.
6. [6] Wang, L., Zhang, D., Raghavan, N., Yao, M., Ma, L., Frost, C.E., et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab. Dispos. 38 (2010), 448–458.
7. [7] Lang, D., Freudenberger, C., Weinz, C., In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans. Drug Metab. Dispos. 37 (2009), 1046–1055.
8. [8] Raghavan, N., Frost, C.E., Yu, Z., He, K., Zhang, H., Humphreys, W.G., et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab. Dispos. 37 (2009), 74–81.
9. [9] Stangier, J., Rathgen, K., Stähle, H., Mazur, D., Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin. Pharmacokinet. 49 (2010), 259–268.
10. [10] Kubitza, D., Becka, M., Mueck, W., Halabi, A., Maatouk, H., Klause, N., et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor. Br. J. Clin. Pharmacol. 70 (2010), 703–712.
11. [11] Leil, T.A., Feng, Y., Zhang, L., Paccaly, A., Mohan, P., Pfister, M., Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin. Pharmacol. Ther. 88 (2010), 375–382.
12. [12] Jönsson, S., Simonsson, U.S.H., Miller, R., Karlsson, M.O., Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study. J. Clin. Pharmacol. 55 (2015), 1268–1279.
13. [13] Kubitza, D., Roth, A., Becka, M., Alatrach, A., Halabi, A., Hinrichsen, H., et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor. Br. J. Clin. Pharmacol. 76 (2013), 89–98.
14. [14] Frost, C.E., Yu, Z., Wang, J., Li, T., Zeigler, C., Schuster, A., et al. Single-dose safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment. Clin. Pharmacol. Ther., 85, 2009, S34.
15. [15] Stangier, J., Stähle, H., Rathgen, K., Roth, W., Shakeri-Nejad, K., Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J. Clin. Pharmacol. 48 (2008), 1411–1419.
16. [16] Mendell, J., Johnson, L., Chen, S., An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J. Clin. Pharmacol. 55 (2015), 1395–1405.
17. [17] Mueck, W., Kubitza, D., Becka, M., Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br. J. Clin. Pharmacol., 2013.
18. [18] Mendell, J., Zahir, H., Matsushima, N., Noveck, R., Lee, F., Chen, S., et al. Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am. J. Cardiovasc. Drugs. 13 (2013), 331–342.
19. [19] Mendell, J., Chen, S., He, L., Desai, M., Parasramupria, D.A., The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. Clin. Drug Investig. 35 (2015), 447–453.
20. [20] Delavenne, X., Ollier, E., Basset, T., Bertoletti, L., Accassat, S., Garcin, A., et al. A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br. J. Clin. Pharmacol. 76 (2013), 107–113.
21. [21] Zhao, Y., Hu, Z.-Y., Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. Br. J. Pharmacol. 171 (2014), 1043–1053.
22. [22] B. Ingelheim, Pradaxa product monograph, (2014).
23. [23] Frost, C.E., Byon, W., Song, Y., Wang, J., Schuster, A.E., Boyd, R.A., et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br. J. Clin. Pharmacol. 79:May (5) (2015), 838–846.
24. ®)) after co-medication with verapamil in healthy subjects. Br. J. Clin. Pharmacol. 75 (2013), 1053–1062.
25. [25] Mueck, W., Kubitza, D., Becka, M., Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br. J. Clin. Pharmacol. 76 (2013), 455–466.
26. [26] BMS, Eliquis Product Monograph, (2012).
27. [27] Kubitza, D., Becka, M., Mueck, W., Zuehlsdorf Rivaroxaban, M., BAY 59-7939)–an oral, direct Factor Xa inhibitor–has no clinically relevant interaction with naproxen. Br. J. Clin Pharmacol 63 (2007), 469–476.
28. [28] Frost, C., Shenker, A., Gandhi, M.D., Pursley, J., Barrett, Y.C., Wang, J., et al. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. Br. J. Clin. Pharmacol, 2014, 3–4.
29. [29] Mendell, J., Lee, F., Chen, S., Worland, V., Shi, M., Samama, M.M., The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor. J. Cardiovasc. Pharmacol. 62 (2013), 212–221.
30. [30] Mendell, J., Zhang, G., He, L., Parasrampuria, D., The effects of erythromycin on the pharmacokinetics and pharmacodynamics of edoxaban. Clin Pharmacol Drug Dev. 3 (2014), 1–59.
31. [31] Ollier, E., Hodin, S., Basset, T., Accassat, S., Bertoletti, L., Mismetti, P., et al. In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors. Fundam. Clin. Pharmacol., 2015.
32. [32] Stangier, J., Stähle, H., Rathgen, K., Fuhr, R., Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin. Pharmacokinet. 47 (2008), 47–59.
33. [33] Moore, K.T., Plotnikov, A.N., Thyssen, A., Vaccaro, N., Ariyawansa, J., Burton, P.B., Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban. J. Cardiovasc. Pharmacol. 58 (2011), 581–588.
34. [34] Härtter, S., Koenen-Bergmann, M., Sharma, A., Nehmiz, G., Lemke, U., Timmer, W., et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br. J. Clin. Pharmacol. 74 (2012), 490–500.
35. [35] Bayer, Xarelto Product Monograph, (2015).
36. [36] Stangier, J., Rathgen, K., Stähle, H., Reseski, K., Körnicke, T., Roth, W., Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am. J. Cardiovasc. Drugs 9 (2009), 59–68.
37. [37] Kubitza, D., Becka, M., Roth, A., Mueck, W., Absence of clinically relevant interactions between rivaroxaban—an oral, direct Factor Xa inhibitor—and digoxin or atorvastatin in healthy subjects. J. Int. Med. Res. 40 (2012), 1688–1707.
38. [38] Stangier, J., Stähle, H., Rathgen, K., Roth, W., Reseski, K., Körnicke, T., Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. J. Clin. Pharmacol. 52 (2012), 243–250.
39. [39] Schulman, S., Kearon, C., Kakkar, A.K., Mismetti, P., Schellong, S., Eriksson, H., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N. Engl. J. Med. Mass. Med. Soc. 361 (2009), 2342–2352.
40. [40] Schulman, S., Kakkar, A.K., Goldhaber, S.Z., Schellong, S., Eriksson, H., Mismetti, P., et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129 (2014), 764–772.
41. [41] EINSTEIN Investigators, Bauersachs, R., Berkowitz, S.D., Brenner, B., Buller, H.R., Decousus, H., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N. Engl. J. Med. 363 (2010), 2499–2510.
42. [42] Agnelli, G., Buller, H.R., Cohen, A., Curto, M., Gallus, A.S., Johnson, M., et al. Oral apixaban for the treatment of acute venous thromboembolism. N. Engl. J. Med. 369 (2013), 799–808.
43. [43] Büller, H.R., Décousus, H., Grosso, M.A., Mercuri, M., Middeldorp, S., Prins, M.H., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N. Engl. J. Med. Mass. Med. Soc. 369 (2013), 1406–1415.
44. [44] Büller, H.R., Prins, M.H., Lensin, A.W.A., Decousus, H., Jacobson, B.F., Minar, E., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N. Engl. J. Med. 366 (2012), 1287–1297.
45. [45] Schulman, S., Kearon, C., Kakkar, A.K., Schellong, S., Eriksson, H., Baanstra, D., et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N. Engl. J. Med. 368 (2013), 709–718.
46. [46] Agnelli, G., Buller, H.R., Cohen, A., Curto, M., Gallus, A.S., Johnson, M., et al. Apixaban for extended treatment of venous thromboembolism. N. Engl. J. Med., 2012.
47. [47] Agnelli, G., Gallus, A., Goldhaber, S.Z., Haas, S., Huisman, M.V., Hull, R.D., et al. Treatment of proximal deep-vein thrombosis with the oral direct factor xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral direct factor xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 116 (2007), 180–187.
48. [48] Buller, H.R., Lensing, A.W.A., Prins, M.H., Agnelli, G., Cohen, A., Gallus, A.S., et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood Am. Soc. Hematol., 112, 2008, 2242.
49. [49] Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J. Thromb. Haemost. 6 (2008), 1313–1318.
50. [50] Jiménez, D., de Miguel-Díez, J., Guijarro, R., Trujillo-Santos, J., Otero, R., Barba, R., et al. Trends in the management and outcomes of acute pulmonary embolism: analysis from the RIETE registry. J. Am. Coll. Cardiol. 67 (2016), 162–170.
51. [51] Mismetti, P., Laporte, S., Pellerin, O., Ennezat, P.-V., Couturaud, F., Elias, A., et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism. JAMA, 313, 2015, 1627.
52. [52] Couturaud, F., Sanchez, O., Pernod, G., Mismetti, P., Jego, P., Duhamel, E., et al. Six months vs extended oral anticoagulation after a first episode of pulmonary embolism. JAMA, 314, 2015, 31.
53. [53] Fox, B.D., Kahn, S.R., Langleben, D., Eisenberg, M.J., Shimony, A., Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ, 345, 2012 e7498–e7498.
54. [54] Cohen, A.T., Hamilton, M., Mitchell, S.A., Phatak, H., Liu, X., Bird, A., et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-Term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS One., 10, 2015, e0144856.
55. [55] Posch, F., Königsbrügge, O., Zielinski, C., Pabinger, I., Ay, C., Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb. Res. 136 (2015), 582–589.
56. [56] Kang, N., Sobieraj, D.M., Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. Thromb. Res. 133 (2014), 1145–1151.
57. [57] Mantha, S., Ansell, J., Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. J. Thromb. Thrombolysis. 39 (2015), 155–165.
58. [58] Jansen, J.P., Fleurence, R., Devine, B., Itzler, R., Barrett, A., Hawkins, N., et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons Good research practices: part 1. Value Health 14 (2011), 417–428.
59. [59] Prins, M.H., Lensing, A.W., Bauersachs, R., van Bellen, B., Bounameaux, H., Brighton, T.A., et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb. J., 11, 2013, 21.
60. [60] Weitz, J.I., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T.A., Cohen, A.T., et al. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism: rationale for and design of the EINSTEIN CHOICE study. Thromb. Haemost. 114 (2015), 645–650.
61. [61] Holster, I.L., Valkhoff, V.E., Kuipers, E.J., Tjwa, E.T.T.L., New oral anticoagulants increase risk for gastrointestinal bleeding − a systematic review and meta-Analysis. Gastroenterology, 2013.
62. [62] De Crem, N., Peerlinck, K., Vanassche, T., Vanheule, K., Debaveye, B., Middeldorp, S., et al. Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thromb. Res., 2015.
63. [63] van Es, N., Coppens, M., Schulman, S., Middeldorp, S., Büller, H.R., Van Es, N., et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124 (2014), 1968–1975.
64. [64] Eisner, M.D., The challenge of subgroup analyses—Reporting without distorting. N. Engl. J. Med. 355:211 (2006), 211–212 (author reply).
65. [65] Assmann, S.F., Pocock, S.J., Enos, L.E., Kasten, L.E., Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 355 (2000), 1064–1069.
66. [66] Pocock, S.J., Assmann, S.E., Enos, L.E., Kasten, L.E., Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat. Med. 21 (2002), 2917–2930.
67. [67] Wang, R., Lagakos, S.W., Ware, J.H., Hunter, D.J., Drazen, J.M., Statistics in medicine — reporting of subgroup analyses in clinical trials. N. Engl. J. Med. 357 (2007), 2189–2194.
68. [68] Committee for Proprietary Medicinal Products (CPMP), Points To Consider on Multiplicity Issues in Clinical, (2002) p. 1–10.
69. [69] Silverstein, M.D., Heit, H.a., Mohr, D.N., Petterson, T.M., O'Fallon, W.M., Melton, L.J., Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch. Intern. Med. 158 (1998), 585–593.
70. [70] Heit, J.A., Silverstein, M.D., Mohr, D.N., Petterson, T.M., Lohse, C.M., O'Fallon, W.M., et al. The epidemiology of venous thromboembolism in the community. Thromb. Haemost. 86 (2001), 452–463.
71. [71] Laporte, S., Mismetti, P., Décousus, H., Uresandi, F., Otero, R., Lobo, J.L., et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation 117 (2008), 1711–1716.
72. [72] Nieto, J.A., Solano, R., Ruiz-Ribó, M.D., Ruiz-Gimenez, N., Prandoni, P., Kearon, C., et al. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J. Thromb. Haemost. 8 (2010), 1216–1222.
73. [73] Weitz, J.I., Hirsh, J., Samama, M.M., 8th edition New Antithrombotic Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 133, 2008, Chest, 234S–256S.
74. [74] Freyburger, G., Macouillard, G., Labrouche, S., Sztark, F., Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb. Res. 127 (2011), 457–465.
75. [75] Bertoletti, L., Quenet, S., Mismetti, P., Hernández, L., Martín-Villasclaras, J.J., Tolosa, C., et al. Clinical presentation and outcome of venous thromboembolism in COPD. Eur. Respir. J. 39 (2012), 862–868.
76. [76] Konstantinides, S., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D., Galie, N., et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur. Heart J. 35 (2014), 3033–3073.
77. [77] Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J., 46, 2015, ehv317.
78. [78] Jaïs, X., D'Armini, A.M., Jansa, P., Torbicki, A., Delcroix, M., Ghofrani, H.A., et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: bENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J. Am. Coll. Cardiol. Am. Coll. Cardiol. Found. 52 (2008), 2127–2134.
79. [79] Ghofrani, H.-A., D'Armini, A.M., Grimminger, F., Hoeper, M.M., Jansa, P., Kim, N.H., et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: n. Engl. J. Med. Mass. Med.Soc. 369 (2013), 319–329.
80. [80] Bertoletti, L., Delavenne, X., Montani, D., Lega, J., Humbert, M., Mismetti, P., Potential pharmacological interactions between oral pulmonary arterial hypertension (PAH) therapies and new oral anticoagulants. Eur. Respir. J., 40, 2012, 274s.
81. [81] Bertoletti, L., Delavenne, X., Montani, D., Antithrombotics in pulmonary hypertension: more work needed before we turn to newer agents!. Eur. Respir. J. 41 (2013), 775–777.
82. [82] Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension − web addenda. Eur. Heart J. 37 (2016), 67–119.
83. [83] Gabriel, L., Delavenne, X., Bedouch, P., Khouatra, C., Bouvaist, H., Cordier, J.-F., et al. Risk of direct oral anticoagulant bioaccumulation in patients with pulmonary hypertension. Respiration, 2016.
84. [84] Davidson, B.L., Verheijen, S., Lensing, A.W.A., Gebel, M., Brighton, T.A., Lyons, R.M., et al. Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Intern. Med. 174 (2014), 947–953.
85. [85] Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.C., Hacke, W., et al. Updated European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17 (2015), 1467–1507.
86. [86] Trujillo-Santos, J., Antonio Nieto, J., Tiberio, G., Piccioli, A., Di Micco, P., Prandoni, P., et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb. Haemost., 2008, 435–439.
87. [87] Nieto, J.A., Solano, R., Trapero Iglesias, N., Ruiz-Giménez, N., Fernández-Capitán, C., Valero, B., et al. Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism. Thromb. Res. 132 (2013), 175–179.
88. [88] Debourdeau, P., Farge, D., Beckers, M., Baglin, C., Bauersachs, R.M., Brenner, B., et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J. Thromb. Haemost. 11 (2013), 71–80.
89. [89] Short, N.J., Connors, J.M., New oral anticoagulants and the cancer patient. Oncologist 19 (2014), 82–93.
90. [90] Burnett, A.E., Mahan, C.E., Vazquez, S.R., Oertel, L.B., Garcia, D.A., Ansell, J., Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J. Thromb. Thrombolysis. Springer US 41 (2016), 206–232.
91. [91] Kearon, C., Akl, E.A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., et al. Antithrombotic Therapy for VTE Disease. 2016, Chest. Elsevier Ltd.
92. [92] Monagle, P., Chan, A.K.C., Goldenberg, N.a., Ichord, R.N., Journeycake, J.M., Nowak-Göttl, U., et al. Antithrombotic Therapy in Neonates and Children: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. 2012, Chest, 141.
93. [93] Schiele, F., van Ryn, J., Canada, K., Newsome, C., Sepulveda, E., Park, J., et al. A specific antidote for dabigatran: functional and structural characterization. Blood 121 (2013), 3554–3562.
94. [94] Glund, S., Stangier, J., Schmohl, M., Gansser, D., Norris, S., van Ryn, J., et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet (London, England) 386 (2015), 680–690.
95. [95] Glund, S., Moschetti, V., Norris, S., Stangier, J., Schmohl, M., van Ryn, J., et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb. Haemost. 113 (2015), 943–951.
96. [96] Pollack, C.V., Reilly, P.a., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R.a., et al. Idarucizumab for dabigatran reversal. N. Engl. J. Med. 373 (2015), 511–520.
97. [97] Lu, G., DeGuzman, F.R., Hollenbach, S.J., Karbarz, M.J., Abe, K., Lee, G., et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat. Med. 19 (2013), 446–451.
98. [98] Siegal, D.M., Curnutte, J.T., Connolly, S.J., Lu, G., Conley, P.B., Wiens, B.L., et al. Andexanet alfa for the reversal of factor xa inhibitor activity. N. Engl. J. Med. 373 (2015), 2413–2424.
99. [99] Mahé, I., Sterpu, R., Bertoletti, L., López-Jiménez, L., Mellado Joan, M., Trujillo-Santos, J., et al. Long-term anticoagulant therapy of patients with venous thromboembolism. What are the practices?. PLoS One., 10, 2015, e0128741.
100. [100] Gouin-Thibault, I., Flaujac, C., Delavenne, X., Quenet, S., Horellou, M.-H., Laporte, S., et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays: a multicentre French GEHT study. Thromb. Haemost. 111 (2014), 240–248.
101. [101] Cuker, A., Siegal, D.M., Crowther, M.A., Garcia, D.A., Laboratory measurement of the anticoagulant activity of the non–vitamin K oral anticoagulants. J. Am. Coll Cardiol. 64 (2014), 1128–1139.
102. [102] Pernod, G., Albaladejo, P., Godier, A., Samama, C.M., Susen, S., Gruel, Y., et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) − March 2013. Arch. Cardiovasc. Dis. 106 (2013), 382–393.
103. [103] Ageno, W., Crowther, M., Baglin, T., Falanga, A., Buller, H., Palareti, G., et al. Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemo. J. Thromb. Haemost. 11 (2013), 177–179.
104. [104] Martin, K., Beyer-Westendorf, J., Davidson, B.L., Huisman, M.V., Sandset, P.M., Moll, S., Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J. Thromb. Haemost. 14:June (6) (2016), 1308–1313.
105. [105] Levy, J.H., Ageno, W., Chan, N.C., Crowther, M., Verhamme, P., Weitz, J.I., When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J. Thromb. Haemost. 14 (2016), 623–627.